Is Quick Heal Tech overvalued or undervalued?

As of February 5, 2025, Quick Heal Technologies Ltd. is considered overvalued with a PE ratio of 393.95 and negative EV to EBITDA, indicating significant profitability concerns and unfavorable comparisons to peers, despite a recent stock price surge.

As of 5 February 2025, Quick Heal Technologies Ltd. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued, particularly highlighted by its PE ratio of 393.95 and an EV to EBITDA ratio of -272.02, which suggests severe profitability concerns. Additionally, the ROCE stands at -7.86%, further emphasizing the challenges the company faces in generating returns on capital.<BR><BR>In comparison to its peers, Quick Heal's valuation metrics are starkly unfavorable; for instance, its PE ratio is substantially higher than industry averages, while its EV to EBITDA is negative, indicating potential operational inefficiencies. Notably, the company’s PEG ratio is 0.00, which raises questions about future growth prospects. Despite a recent surge in stock price, with a 1-week return of 22.18% compared to the Sensex's 1.38%, the overall valuation suggests that Quick Heal Technologies Ltd. remains overvalued in the current market landscape.

Who are in the management team of Quick Heal Tech?

As of March 2022, the management team of Quick Heal Tech includes Kailash Katkar (Managing Director & CEO), Sanjay Katkar (Joint Managing Director & CTO), and several independent directors, contributing diverse expertise to the company's strategic and operational management.

As of March 2022, the management team of Quick Heal Tech includes:<BR><BR>1. Kailash Sahebrao Katkar - Managing Director & CEO<BR>2. Sanjay Sahebrao Katkar - Joint Managing Director & CTO<BR>3. Shailesh Lakhani - Director<BR>4. Apurva Pradeep Joshi - Independent Director<BR>5. Amitabha Mukhopadhyay - Independent Director<BR>6. Bhushan Gokhale - Independent Director<BR>7. Srinivasa Rao Anasingaraju - Company Secretary & Compliance Officer<BR>8. Richard Stiennon - Independent Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its strategic direction and operational management.

Has Quick Heal Tech declared dividend?

Quick Heal Technologies Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of August 30, 2024. While recent returns have been negative, the company has shown significant growth over the longer term, particularly a total return of 243.34% over the past 5 years.

Quick Heal Technologies Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 30 Aug 24<BR><BR>Dividend Yield: 0.82%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -45.2%, with a dividend return of 0%, resulting in a total return of -45.2%.<BR><BR>Over the past year, the price return was -21.75%, the dividend return was 0.69%, leading to a total return of -21.06%.<BR><BR>In the 2-year period, the price return was 118.34%, the dividend return was 3.43%, culminating in a total return of 121.77%.<BR><BR>For the 3-year period, the price return was 105.86%, the dividend return was 6.71%, resulting in a total return of 112.57%.<BR><BR>In the last 4 years, the price return was 51.9%, with a dividend return of 5.15%, leading to a total return of 57.05%.<BR><BR>Over the past 5 years, the price return was 231.23%, the dividend return was 12.11%, resulting in a total return of 243.34%.<BR><BR>Overall, Quick Heal Technologies Ltd has declared a dividend, and while the recent returns over shorter periods have been negative, the longer-term returns show significant growth, particularly in the 5-year period.

Who are the peers of the Quick Heal Tech?

Quick Heal Tech's peers include C.E. Info System, Tanla Platforms, Moschip Tech, Nucleus Soft, Technvision Ven, Blue Cloud Soft, Ramco Systems, Unicommerce, IRIS Business, and Subex. Notably, IRIS Business has the highest 1-year return at 47.93%, while Blue Cloud Soft has the lowest at -85.59%.

Peers: The peers of Quick Heal Tech are C.E. Info System, Tanla Platforms, Moschip Tech., Nucleus Soft., Technvision Ven., Blue Cloud Soft., Ramco Systems, Unicommerce, IRIS Business, and Subex.<BR><BR>Quality Snapshot: Excellent management risk is observed at C.E. Info System, Nucleus Soft., and Unicommerce, while Average management risk is found at Tanla Platforms, Technvision Ven., Blue Cloud Soft., Ramco Systems, IRIS Business, and Subex. Good growth is noted at C.E. Info System, Tanla Platforms, Unicommerce, and the rest have either Below Average or Average growth. Excellent capital structure is seen at C.E. Info System, Nucleus Soft., Technvision Ven., Unicommerce, and IRIS Business, while Average capital structure is found at Blue Cloud Soft. and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is IRIS Business at 47.93%, while the peer with the lowest is Blue Cloud Soft. at -85.59%. Quick Heal Tech's 1-year return of -28.50% is better than Blue Cloud Soft. but worse than IRIS Business. Additionally, the six-month return is negative for Moschip Tech., Blue Cloud Soft., and Subex.

What does Quick Heal Tech do?

Quick Heal Technologies Ltd is a small-cap company specializing in cybersecurity solutions, with a recent net sales of 651 Cr and a net profit of -32 Cr as of March 2025. The company has a market cap of INR 2,074 Cr and operates with a P/E ratio of 423.00.

Overview:<BR>Quick Heal Technologies Ltd is a small-cap company operating in the Software Products industry, specializing in cybersecurity solutions.<BR><BR>History:<BR>Quick Heal Technologies Limited was incorporated in 1995 as CAT Computer Services Private Limited and later changed its name in 2007. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 651 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -32 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 2,074 Cr (Small Cap) <BR><BR>Key Metrics:<BR>P/E: 423.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.78% <BR>Debt-Equity: -0.44 <BR>Return on Equity: 1.14% <BR>Price to Book: 4.66 <BR><BR>Contact Details:<BR>Address: Marvel Edge 7th Floor, Office No 7010 C&D Viman Nagar Pune Maharashtra : 411014 <BR>Tel: 91-20-66813232 <BR>Email: cs@quickheal.com <BR>Website: http://www.quickheal.com

Who are the top shareholders of the Quick Heal Tech?

The top shareholder of Quick Heal Tech is Sanjay Sahebrao Katkar, holding 28.86%. Other notable shareholders include 22 foreign institutional investors with 2.02%, a mutual fund with 1.13%, and individual investors collectively holding 19.14%.

The top shareholders of Quick Heal Tech include the promoters, with Sanjay Sahebrao Katkar holding the largest share at 28.86%. There are no pledged promoter holdings. Additionally, institutional investors include 22 foreign institutional investors (FIIs) who collectively hold 2.02%, and one mutual fund scheme that holds 1.13%. Among public shareholders, the highest holding is by Carnelian Structural Shift Fund at 1.22%. Individual investors collectively hold 19.14% of the company.

How big is Quick Heal Tech?

As of 24th July, Quick Heal Technologies Ltd has a market capitalization of 1,820.00 Cr, with recent net sales of 279.53 Cr and a net profit of 5.04 Cr. Shareholder's funds are 437.00 Cr, and total assets amount to 509.23 Cr.

As of 24th July, Quick Heal Technologies Ltd has a market capitalization of 1,820.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 279.53 Cr and a Net Profit of 5.04 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 437.00 Cr and Total Assets of 509.23 Cr.

When is the next results date for Quick Heal Tech?

The next results date for Quick Heal Tech is 15 October 2025.

The next results date for Quick Heal Tech is scheduled for 15 October 2025.

Are Quick Heal Tech latest results good or bad?

Quick Heal Technologies' latest results show a significant quarterly profit increase of 90.60% and revenue growth of 13.65%, but a troubling 70.66% decline in half-yearly net profit and low return on equity raise concerns about its overall financial health and core operations. Investors should be cautious due to these underlying issues despite recent improvements.

Quick Heal Technologies' latest results present a mixed picture. On one hand, the company reported a significant increase in net profit for Q2 FY26, reaching ₹7.91 crores, which is a remarkable 90.60% increase year-on-year. Revenue also grew by 13.65% year-on-year, totaling ₹83.52 crores. Additionally, the operating margin improved to 11.05%, a positive shift from the previous quarter's negative margin.<BR><BR>However, despite these improvements, there are serious concerns regarding the company's overall profitability. The half-yearly net profit has collapsed by 70.66% compared to the same period last year, indicating deeper structural issues. The return on equity (ROE) is critically low at 1.14%, raising questions about the company's ability to generate adequate returns on shareholder capital. Furthermore, Quick Heal's reliance on non-operating income to bolster profits is troubling, as it suggests challenges in its core operations.<BR><BR>In summary, while the quarterly results show some positive trends, the broader financial health of Quick Heal is concerning, with significant profitability challenges and competitive pressures in the cybersecurity market. Investors should approach with caution, considering both the recent improvements and the underlying issues.

How has been the historical performance of Quick Heal Tech?

Quick Heal Tech has experienced a significant decline in financial performance, with net sales dropping from INR 341.90 crore in March 2022 to INR 279.53 crore in March 2025, and operating profit turning negative at -INR 6.59 crore. Key metrics such as profit before tax and earnings per share have also sharply decreased during this period.

Answer:<BR>The historical performance of Quick Heal Tech shows a fluctuating trend in key financial metrics over the years, with significant declines in recent periods.<BR><BR>Breakdown:<BR>Quick Heal Tech's net sales have seen a decline from INR 341.90 crore in March 2022 to INR 279.53 crore in March 2025, with a slight recovery from INR 278.09 crore in March 2023. The total operating income followed a similar pattern, peaking at INR 341.90 crore in March 2022 and dropping to INR 279.53 crore by March 2025. The company's total expenditure, excluding depreciation, increased from INR 235.04 crore in March 2022 to INR 286.12 crore in March 2025, contributing to an operating profit (PBDIT) that turned negative at -INR 6.59 crore in March 2025, down from a high of INR 126.06 crore in March 2022. Profit before tax also fell sharply from INR 108.68 crore in March 2022 to INR 1.00 crore in March 2025, while profit after tax decreased from INR 83.19 crore to INR 5.04 crore in the same period. The earnings per share (EPS) reflected this downturn, dropping from INR 14.34 in March 2022 to INR 0.93 in March 2025. On the balance sheet, total assets decreased from INR 715.88 crore in March 2022 to INR 517.10 crore in March 2025, while total liabilities also decreased from INR 715.88 crore to INR 517.10 crore, indicating a consistent reduction in both assets and liabilities. The cash flow from operating activities turned negative at -INR 22.00 crore in March 2025, contrasting with positive cash flows in earlier years. Overall, Quick Heal Tech has experienced a significant decline in financial performance over the past few years.

Is Quick Heal Tech technically bullish or bearish?

As of December 2, 2025, Quick Heal Tech's technical stance is bearish with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators, and a significant year-to-date decline of 54.12% compared to the Sensex's 8.96%.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Quick Heal Tech is bearish with moderate strength. Key indicators driving this stance include the bearish signals from the daily moving averages and the weekly Bollinger Bands, alongside a bearish monthly MACD. Although the weekly MACD and KST show mildly bullish tendencies, the overall monthly indicators remain bearish, reinforcing the bearish outlook. The stock's recent performance, with a significant year-to-date decline of 54.12% compared to the Sensex's 8.96%, further supports this bearish sentiment.

Which are the latest news on Quick Heal Tech?

Should I buy, sell or hold Quick Heal Tech?

Why is Quick Heal Tech falling/rising?

As of 03-Dec, Quick Heal Technologies Ltd's stock price is Rs 289.30, down 4.14%, and has significantly underperformed the Sensex with a year-to-date decline of 55.99%. The stock shows bearish trends, poor long-term growth metrics, and decreased institutional investor confidence.

As of 03-Dec, Quick Heal Technologies Ltd is experiencing a decline in its stock price, currently at Rs 289.30, reflecting a change of -12.5 (-4.14%). The stock has been underperforming significantly compared to the benchmark Sensex, with a 1-week decline of -4.57% against the Sensex's -0.59%. Over the past month, the stock has dropped by -11.07%, while the Sensex has gained +1.34%. Year-to-date, Quick Heal's stock has plummeted by -55.99%, contrasting sharply with the Sensex's +8.92% increase.<BR><BR>Today's performance indicates that the stock has underperformed its sector by -5.01% and has seen consecutive losses over the last two days, totaling a decline of -5.95%. The stock reached an intraday low of Rs 288.95, and trading activity suggests a lack of investor interest, with a delivery volume that has decreased by -24.76% compared to the 5-day average.<BR><BR>Moreover, Quick Heal Technologies is trading below its moving averages across various time frames, indicating a bearish trend. The company also faces significant challenges, including poor long-term growth metrics, with net sales declining at an annual rate of -0.80% and operating profit decreasing by -179.58% over the last five years. Recent financial results show a drastic drop in profit after tax (PAT) by -70.66% in the latest six months, alongside a low debtors turnover ratio and cash reserves.<BR><BR>Institutional investor participation has also waned, with a decrease in their stake by -0.91% over the previous quarter, suggesting a lack of confidence in the company's prospects. Overall, these factors contribute to the stock's downward trajectory, reflecting a broader trend of underperformance in comparison to the market.